Systemic chemotherapy for hepatocellular carcinoma

  • Nobuo Okazaki
  • Shuichi Okada
  • Haruhiko Nose
  • Kazunori Aoki


After a promising preliminary report by Olweny et al. was published in 1975 [1], doxorubicin came into use and was considered the most reliable anticancer agent for hepatocellular carcinoma (HCC). However, in recent well-controlled Phase 11 trials which included doxorubicin, it was demonstrated that no active anticancer agent for HCC shows more than a 15% response rate reproducibly [2].


Hepatocellular Carcinoma Clin Oncol Anticancer Agent Systemic Chemotherapy Transcatheter Arterial Embolization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Olweny CLM, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H (1975) Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 36: 1250–1257PubMedCrossRefGoogle Scholar
  2. 2.
    Falkson G, Coetzer B (1987) Chemotherapy of primary liver cancer. In: Okuda K, Ishak KJ (eds) Neoplasms of the liver. Springer-Verlag, Tokyo, pp 331–326Google Scholar
  3. 3.
    Okamoto E, Yamanaka N, Toyosaka Y, Tanaka N, Yabuki K (1987) Current status of hepatic resection in the treatment of hepatocellular car cinoma. In: Okuda K, Ishak KJ (eds) Neoplasms of the liver. Springer-Verlag, Tokyo, pp 353–363Google Scholar
  4. 4.
    Okuda K, Ohtsuki T, Obata H, Tominatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918–928PubMedCrossRefGoogle Scholar
  5. 5.
    Einhorn LH (1981) Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41: 3275–3280PubMedGoogle Scholar
  6. 6.
    Yamasaki S, Hasegawa H, Makuuchi M (1981) Clinicopathological observation of minute liver cancer and the new method of hepatectomy. An Analysis of 27 cases. Acta Hepatol Jpn 22: 1714–1724CrossRefGoogle Scholar
  7. 7.
    Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, Kondo F, Kondo Y (1990) Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 5: 616–626PubMedCrossRefGoogle Scholar
  8. 8.
    Yamada R, Sato M, Kawabata T, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397–401PubMedGoogle Scholar
  9. 9.
    The Liver Study Group of Japan (1990) Primary liver cancer in Japan (ninth report)Google Scholar
  10. 10.
    WHO (1979) WHO handbook for reporting results of cancer treatment, WHO Offset Publication, No. 48Google Scholar
  11. 11.
    Oken MM, Greech RH, Horton J, Davis TE, McFadden Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655PubMedCrossRefGoogle Scholar
  12. 12.
    Okazaki N, Yoshida T, Yoshino M, Okada S, Shimada Y, Moriyama N, Takayasu K (1991) Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report. Jpn J Clin Oncol 21: 69–67Google Scholar
  13. 13.
    Okada S, Okazaki N, Nose H, Ohkura H, Sugano K, Aoki K (to be published) (1992) Evaluation of chemotherapeutic effects for hepatocellular carcinoma based on survival analysis. Acta Hepatol JpnGoogle Scholar
  14. 14.
    Okazaki N, Yoshino M, Yoshida T, Hizikata A, Hasegawa H (1986) Systemic chemotherapy of hepatocellular carcinoma. Jpn J Cancer Chemother 13: 584–1588Google Scholar
  15. 15.
    Okazaki N, Yoshino M, Yoshida T, Hijikata A (1985) A controlled study of intravenous doxorubicin versus oral tegafur in patients with hepatocellular carcinoma. J Jpn Soc Cancer Ther 20: 556–561Google Scholar
  16. 16.
    Tokyo Liver Cancer Chemotherapy Study Group (1985) Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Jpn J Clin Oncol 15: 559–562Google Scholar
  17. 17.
    Yoshino M, Okazaki N, Yoshida T, Kanda Y, Miki M, Oda H, Sasagawa Y, Hayashi S, Hoshimoto N (1989) A phase II study of etoposide in patients with hepatocellular carcinoma by Tokyo Liver Cancer Chemotherapy Study group. Jpn J Clin Oncol 19: 120–122PubMedGoogle Scholar
  18. 18.
    Yoshida T, Okazaki N, Yoshino M, Ohkura H, Miyamoto K, Shimada Y (1988) Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol 124: 1897–1898CrossRefGoogle Scholar
  19. 19.
    Yoshida T, Okazaki N, Yoshino M, Ohkura H, Shimada Y (1990) Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer 26: 545–546PubMedGoogle Scholar
  20. 20.
    Okada S, Okazaki N, Nose H, Aoki K, Simada Y (to be published) (1992) Phase II trial of cisplatin for hepatocellular carcinoma. Eur J CancerGoogle Scholar
  21. 21.
    Olweny CLM, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK (1980) Further experiences in treating patients with hepatocellular carcinoma in Uganda. Cancer 46: 2717–2722PubMedCrossRefGoogle Scholar
  22. 22.
    Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK (1984) Doxorubicin (75mg/m2) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68: 487–491PubMedGoogle Scholar
  23. 23.
    Falkson G, Maclntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer: An Eastan Cooperative Oncology Group Trial. Cancer 54: 970–977PubMedCrossRefGoogle Scholar
  24. 24.
    Lai CL, Wu PC, Chan GCB, Lok ASF, Lin HJ (1988) Doxorubicin verus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62: 479–483PubMedCrossRefGoogle Scholar
  25. 25.
    Höchster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM (1985) The efficacy of high-dose 4’Epirubicin ( Epirubicin ): Activity in hepatocellular carcinoma. J Clin Oncol 3: 1535–1540PubMedGoogle Scholar
  26. 26.
    Shiu W, Leung N, Li M, Leug WT, Li AKG (1988) The efficacy of high-dose 4’Epidoxorubicin in hepatocellular carcinoma. Jpn J Clin Oncol 18: 235–237PubMedGoogle Scholar
  27. 27.
    Davis RB, Van Echo DA, Leone LA, Henderson ES (1986) Phase II trial of mitoxantrone in advanced primary liver cancer. A Cancer Leukemia Group B Study. Cancer Treat Rep 70: 1125–1126PubMedGoogle Scholar
  28. 28.
    Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, Creech RH, Schutt AJ (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60: 2141–2145PubMedCrossRefGoogle Scholar
  29. 29.
    Ohya T, Kikuchi S, Kato K, Takei T, Takeichi M, Nakano S, Watahiki M, Koyama T, Yamamoto M, Komatsu T, Miwa N, Kasugai T, Hisano N, Tuboi Y, Kikuchi S, Tomusa A (1982) Clinical studies of chemotherapy for primary hepatocellular carcinoma. Jpn J Cancer Chemother 9: 1623–1627Google Scholar
  30. 30.
    Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen HH (1981) Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17: 1079–1082PubMedCrossRefGoogle Scholar
  31. 31.
    Shiu W, Mok SD, Leung N, Li M, Zacharia A, Li A, Martin C (1987) Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma. Jpn J Clin Oncol 17: 113–115PubMedGoogle Scholar
  32. 32.
    Ravry MJR, Omura GA, Bartolucii AA, Einhorn L, Kramer B, Davila E (1986) Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: A Southern Cancer Study Group Trial. Cancer Treat Rep 70: 311–312PubMedGoogle Scholar
  33. 33.
    Okazaki N, Yoshino M, Yoshida T (1989) Chemotherapy for hepatocellular carcinoma. Kan Tan Sui 18: 239–242Google Scholar

Copyright information

© Springer-Verlag Tokyo 1992

Authors and Affiliations

  • Nobuo Okazaki
    • 1
  • Shuichi Okada
    • 1
  • Haruhiko Nose
    • 1
  • Kazunori Aoki
    • 1
  1. 1.Department of Internal MedicineNational Cancer Center HospitalChuo-ku, TokyoJapan

Personalised recommendations